SGLT2 inhibition to target kidney aging

Area of Science:

• Gerontology
• Nephrology
• Pharmacology

Background:

• Chronic kidney disease (CKD) and renal aging share hallmarks like cellular senescence, inflammation, and oxidative stress.
• Cellular signaling pathways implicated in aging and CKD offer potential therapeutic targets.
• Sodium-glucose co-transporter 2 inhibitors (SGLT2is) exhibit significant benefits across the cardiorenal spectrum.

Purpose of the Study:

• To review experimental evidence on SGLT2is' effects on molecular pathways related to senescence and aging in the kidney.
• To explore the potential of SGLT2is in mitigating kidney aging and senescence-related damage.
• To elucidate the role of SGLT2is in managing CKD progression in the context of aging.

Main Methods:

• Literature review of experimental studies.
• Analysis of molecular pathways involved in cellular senescence and kidney aging.
• Examination of SGLT2is' impact on these pathways.

Main Results:

• SGLT2is demonstrate effects on molecular pathways modulating senescence, aging, and parenchymal damage in the kidney.
• Evidence suggests SGLT2is can counteract key aging processes relevant to CKD.
• The precise mechanisms underlying SGLT2is' renal benefits are still under investigation.

Conclusions:

• SGLT2is hold potential as a therapeutic strategy for managing kidney aging and CKD.
• Targeting senescence and aging pathways with SGLT2is may reduce CKD progression.
• Further research is needed to fully understand and optimize SGLT2is' role in kidney care.